Andros Pharmaceuticals Co., Ltd.(TW:6917)
NT$31.00+1.35 (+4.55%)
TW:6917
Andros Pharmaceuticals Co., Ltd. financials statements
NT$31.00
At close:+1.35 (+4.55%)
Andros Pharmaceuticals Co., Ltd. (6917) Ratios
Andros Pharmaceuticals Co., Ltd. Ratios
TW:6917's free cash flow for Q2 2026 was NT$-25.46M. For the 2026 fiscal year, TW:6917's free cash flow was increased by NT$0.00 and operating cash flow was NT$-25.46M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.97 | 13.81 | 14.16 | 13.62 | 4.42 |
| Quick Ratio | 13.91 | 13.77 | 14.13 | 13.57 | 4.36 |
| Cash Ratio | 1.96 | 1.47 | 8.41 | 4.48 | 0.83 |
| Solvency Ratio | -1.09 | -1.53 | -1.07 | -0.69 | -0.59 |
| Operating Cash Flow Ratio | -1.66 | -2.99 | -1.46 | -1.82 | -2.03 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -15780.60 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 339.73M | NT$ 317.06M | NT$ 394.65M | NT$ 217.91M | NT$ 26.65M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.05 | 0.05 | 0.09 | 0.29 |
| Debt-to-Equity Ratio | 0.03 | 0.06 | 0.06 | 0.11 | 0.50 |
| Debt-to-Capital Ratio | 0.03 | 0.05 | 0.05 | 0.10 | 0.33 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.12 | 1.12 | 1.18 | 1.75 |
| Debt Service Coverage Ratio | -255.07 | -207.58 | -139.82 | -74.03 | -59.52 |
| Interest Coverage Ratio | -279.10 | -262.79 | -167.52 | -87.74 | -73.22 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.37 | 0.61 | 0.76 | 0.96 | 1.29 |
| Net Debt to EBITDA | 0.54 | 0.23 | 3.93 | 1.66 | -0.67 |
| Profitability Margins | |||||
| Gross Profit Margin | -89.47% | 4.93% | 38.88% | 56.39% | 64.55% |
| EBIT Margin | -1363.30% | -38306.90% | -8409.57% | -2376.59% | -274.98% |
| EBITDA Margin | -1241.38% | -35294.09% | -7639.75% | -2005.20% | -223.36% |
| Operating Profit Margin | -1363.30% | -44142.86% | -9156.52% | -2376.59% | -274.98% |
| Pretax Profit Margin | -964.76% | -38474.88% | -8464.22% | -2403.68% | -278.74% |
| Net Profit Margin | -969.29% | -38561.08% | -8466.96% | -2403.74% | -278.92% |
| Continuous Operations Profit Margin | -969.29% | -38561.08% | -8466.96% | -2403.74% | -278.92% |
| Net Income Per EBT | 100.47% | 100.22% | 100.03% | 100.00% | 100.07% |
| EBT Per EBIT | 70.77% | 87.16% | 92.44% | 101.14% | 101.37% |
| Return on Assets (ROA) | -9.62% | -17.73% | -12.88% | -12.49% | -30.88% |
| Return on Equity (ROE) | -10.43% | -19.86% | -14.47% | -14.73% | -54.08% |
| Return on Capital Employed (ROCE) | -14.23% | -21.59% | -14.83% | -13.14% | -35.69% |
| Return on Invested Capital (ROIC) | -14.09% | -21.32% | -14.68% | -12.93% | -34.13% |
| Return on Tangible Assets | -9.62% | -17.73% | -12.88% | -12.49% | -30.88% |
| Earnings Yield | -4.78% | -12.49% | -7.71% | -3.90% | -4.28% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.12 | 0.41 | 1.81 | 0.26 | 2.94 |
| Payables Turnover | 53.36 | 0.00 | 98.40 | 0.00 | 0.00 |
| Inventory Turnover | 6.85 | 0.21 | 0.45 | 0.69 | 4.46 |
| Fixed Asset Turnover | 0.26 | 0.01 | 0.03 | 0.05 | 0.35 |
| Asset Turnover | 0.01 | 0.00 | 0.00 | 0.01 | 0.11 |
| Working Capital Turnover Ratio | 0.02 | 0.00 | 0.00 | 0.01 | 0.19 |
| Cash Conversion Cycle | 117.74 | 2650.82 | 1004.76 | 1957.22 | 205.82 |
| Days of Sales Outstanding | 71.32 | 888.23 | 201.32 | 1428.04 | 124.06 |
| Days of Inventory Outstanding | 53.26 | 1762.59 | 807.15 | 529.18 | 81.76 |
| Days of Payables Outstanding | 6.84 | 0.00 | 3.71 | 0.00 | 0.00 |
| Operating Cycle | 124.58 | 2650.82 | 1008.47 | 1957.22 | 205.82 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.98 | -2.16 | -1.28 | -1.08 | -1.32 |
| Free Cash Flow Per Share | -1.00 | -2.29 | -1.30 | -1.08 | -1.32 |
| Dividend Paid and CapEx Coverage Ratio | -45.90 | -17.45 | -80.14 | -777.37 | 0.00 |
| Capital Expenditure Coverage Ratio | -45.90 | -17.45 | -80.14 | -777.37 | 0.00 |
| Operating Cash Flow Coverage Ratio | -2.70 | -3.58 | -1.72 | -1.14 | -1.04 |
| Operating Cash Flow to Sales Ratio | -8.19 | -388.68 | -57.94 | -20.88 | -2.69 |
| Free Cash Flow Yield | -4.13% | -13.31% | -5.34% | -3.39% | -4.13% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -20.95 | -8.00 | -12.97 | -25.58 | -23.34 |
| Price-to-Sales (P/S) Ratio | 202.82 | 3088.26 | 1097.99 | 616.49 | 65.21 |
| Price-to-Book (P/B) Ratio | 2.18 | 1.59 | 1.88 | 3.78 | 12.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -24.23 | -7.51 | -18.72 | -29.49 | -24.20 |
| Price-to-Operating Cash Flow Ratio | -24.76 | -7.95 | -18.95 | -29.53 | -24.20 |
| Price-to-Earnings Growth (PEG) Ratio | 0.45 | -0.53 | -0.26 | 2.92 | -7.76 |
| Enterprise Value Multiple | -15.80 | -8.52 | -10.44 | -29.09 | -29.87 |
| Enterprise Value | 1.09B | 610.10M | 641.99M | 999.10M | 888.07M |
| EV to EBITDA | -15.80 | -8.52 | -10.44 | -29.09 | -29.87 |
| EV to Sales | 196.17 | 3005.39 | 797.50 | 583.25 | 66.71 |
| EV to Free Cash Flow | -23.44 | -7.31 | -13.60 | -27.90 | -24.76 |
| EV to Operating Cash Flow | -23.95 | -7.73 | -13.76 | -27.94 | -24.76 |
| Tangible Book Value Per Share | 11.14 | 10.81 | 12.92 | 8.46 | 2.53 |
| Shareholders’ Equity Per Share | 11.14 | 10.81 | 12.93 | 8.46 | 2.53 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.12 | 0.01 | 0.02 | 0.05 | 0.49 |
| Net Income Per Share | -1.16 | -2.15 | -1.87 | -1.25 | -1.37 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.71 | 1.00 | 1.01 | 1.01 | 1.01 |
| Research & Development to Revenue | 10.49 | 353.49 | 70.63 | 20.77 | 2.44 |
| SG&A to Revenue | 2.25 | 87.99 | 21.32 | 7.09 | 0.82 |
| Stock-Based Compensation to Revenue | 0.33 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | 1.01 | 0.68 | 0.87 | 0.97 |
Currency in TWD
